Menopause Supplements: Benefits, Evidence, Dosing, and Side Effects

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Menopause is the permanent cessation of menstrual cycles, defined retrospectively as occurring after 12 consecutive months of amenorrhea in the absence of other pathological or physiological causes [1]. It typically occurs at approximately age 51 and results from the exhaustion of ovarian follicles, leading to a profound decline in estrogen and progesterone production [1][2]. Vasomotor symptoms — hot flashes and night sweats — affect 75-80% of menopausal women, often persisting for 1 to 6 years, and represent the most common reason women seek treatment [2][3].

The decline in estrogen has far-reaching consequences beyond vasomotor symptoms. It contributes to genitourinary symptoms (vaginal dryness, urinary urgency) in 50-75% of women, sleep disturbances, mood changes, accelerated bone loss (averaging 1-5% annually in the first 5-7 years post-menopause), and increased cardiovascular risk [2][4]. The Framingham Heart Study reported a 2.6-fold higher incidence of cardiovascular events in postmenopausal women compared to their premenopausal counterparts, independent of age and other risk factors [5].

While menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms — reducing frequency by 75-90% — many women cannot or prefer not to use MHT due to contraindications (personal or family history of breast cancer, thromboembolic disease) or personal preference [6][7]. This has driven interest in plant-based alternatives, collectively known as phytoestrogens.

Phytoestrogens are naturally occurring plant compounds with structural similarity to 17-beta-estradiol, the primary human estrogen [8]. They bind to estrogen receptors (ERalpha and ERbeta) and exert weak estrogenic or anti-estrogenic effects depending on the tissue, endogenous estrogen levels, and the specific compound [8][9]. The three main categories of phytoestrogens used for menopausal symptoms are:

• Soy isoflavones — derived from soybeans and soy germ; the most extensively studied phytoestrogens for menopause
• Red clover isoflavones — derived from the aerial parts of Trifolium pratense; contain additional isoflavones not found in soy
• Black cohosh — derived from the root and rhizome of Actaea racemosa (Cimicifuga racemosa); mechanism of action remains unclear and may not involve estrogen receptors

Additionally, progesterone cream (applied topically) is sometimes used alongside phytoestrogens for menopausal symptom relief, though it is a hormone rather than a phytoestrogen.

This article reviews the clinical evidence for each of these supplements, covering efficacy for vasomotor symptoms, bone health, cardiovascular effects, and safety considerations.

Forms and Bioavailability

Soy Isoflavones

Soy isoflavones exist in two primary molecular forms: aglycones (the active estrogen-like compounds without attached sugar molecules) and glycosides (larger molecules with sugar molecules attached, also called glucosidic isoflavones) [8][10]. Nearly all supplements contain a mixture of both forms. This distinction matters for dosing because aglycone forms are the biologically active compounds, while glycoside forms include additional molecular weight from the sugar moiety.

The three principal soy isoflavone aglycones are:

• Genistein — the most estrogenically potent soy isoflavone; predominant in soybean concentrates (approximately 50% of total isoflavones in products using soy bean, such as Novasoy) [10]
• Daidzein — predominant in soy germ concentrates (such as SoyLife), where genistein represents less than 20% of total isoflavones [10]
• Glycitein — present in smaller amounts in both sources

The corresponding glycoside forms are named genistin, daidzin, and glycitin (note the "-in" suffix for glycosides versus "-ein" for aglycones) [10].

Bioavailability considerations:

Isoflavone glycosides must be hydrolyzed by intestinal beta-glucosidases to release the aglycone before absorption can occur [8][11]. Absorption efficiency varies considerably between individuals, influenced by gut microbiome composition, concurrent food intake, and genetic factors.

A critical factor in isoflavone metabolism is the ability to produce equol, a metabolite of daidzein formed by specific intestinal bacteria [11][12]. Equol has substantially greater estrogenic activity than its parent compound daidzein and binds more avidly to estrogen receptor beta (ERbeta) [12]. Only approximately 30-50% of individuals harbor the equol-producing bacteria, with prevalence higher in Asian populations (50-60%) compared to Western populations (25-30%) [11][12]. This inter-individual variation in equol production may partly explain inconsistent results across clinical trials and the greater apparent efficacy of soy in Asian epidemiological studies.

Label confusion: Manufacturers use inconsistent labeling practices. Some products declare the weight of active aglycone isoflavones, while others include the weight of the attached sugar molecules, making direct comparisons between products difficult [10]. When a label lists "total isoflavones," the aglycone content may be 40-60% of that figure.

Taking isoflavones with a meal high in carbohydrates may enhance absorption [10]. Dividing the daily dose into at least two servings helps maintain more constant blood levels.

Red Clover Isoflavones

Red clover (Trifolium pratense) contains the same isoflavones found in soy — genistein and daidzein — plus two additional isoflavones:

• Biochanin A — a methylated precursor of genistein; demethylated in vivo to genistein
• Formononetin — a methylated precursor of daidzein; demethylated in vivo to daidzein

Red clover extracts are typically standardized to total isoflavone content, with commercial preparations generally providing 40-160 mg of isoflavones per daily dose [13][14]. Because biochanin A and formononetin require demethylation before they become active, the effective isoflavone exposure from red clover depends on individual metabolic capacity.

Red clover isoflavones are extracted from the aerial parts (leaves and flowers) of the plant, in contrast to soy isoflavones which come from the bean or germ.

Black Cohosh

Black cohosh (Actaea racemosa, formerly Cimicifuga racemosa) is a perennial plant native to North America, belonging to the buttercup family [3][15]. Preparations are made from the roots and rhizomes and are available as powdered whole herb, liquid extracts, and dried extracts in capsule or tablet form [15].

The chemical composition of black cohosh is complex and includes:

• Triterpene glycosides — including actein, 23-epi-26-deoxyactein, and cimicifugoside; extracts are frequently standardized to contain at least 2.5% triterpene glycosides or deliver at least 1 mg per daily dose [3][15][16]
• Resins — such as cimicifugin
• Aromatic acid derivatives — including caffeic, isoferulic, and fukinolic acids

Despite the common practice of standardization to triterpene glycoside content, research suggests these may not be the active compounds responsible for symptom relief [15][16]. The actual active constituents and mechanism of action remain unknown.

Remifemin, the most widely studied commercial black cohosh product, is an isopropanol extract standardized to be equivalent to 40 mg of black cohosh root/rhizome per daily dose of two tablets, though it is not standardized to triterpene glycoside content [15][17]. The product has been reformulated over time, complicating interpretation of studies conducted with different formulations [16].

The mechanism of action of black cohosh remains debated. Studies have yielded inconsistent results regarding whether it affects estrogen levels, luteinizing hormone, or follicle-stimulating hormone [3][18]. Some researchers hypothesize that black cohosh may work through serotonergic pathway modulation, antioxidant activity, anti-inflammatory effects, or selective estrogen receptor modulator (SERM)-like activity [3][18][19]. It is not clear whether black cohosh affects the structure and activity of vaginal and uterine tissues [3][18].

Progesterone Cream

Topical progesterone cream delivers the hormone through the skin. Different products contain varying concentrations, typically ranging from 16 to 25 mg of progesterone per gram of cream [10]. The bioavailability of transdermally applied progesterone is variable, and standard doses probably provide insufficient progesterone to protect the uterus from the stimulating effects of unopposed estrogen — a critical clinical consideration [10].

Comparison Table

Supplement	Active Compounds	Standardization	Mechanism	Bioavailability Notes
Soy Isoflavones	Genistein, Daidzein, Glycitein	Aglycone or total isoflavones (variable labeling)	Weak ER binding (preferentially ERbeta); equol production dependent	30-50% of people produce equol; take with carbohydrate-rich meals
Red Clover	Genistein, Daidzein, Biochanin A, Formononetin	Total isoflavones (typically 40 mg/day)	Same as soy after demethylation	Biochanin A and formononetin require metabolic activation
Black Cohosh	Triterpene glycosides, resins, aromatic acids	≥2.5% triterpene glycosides or ≥1 mg/day	Unknown; possibly serotonergic, SERM-like, or anti-inflammatory	Active compounds unidentified; preparations vary widely
Progesterone Cream	Progesterone	16-25 mg per gram of cream	Direct hormonal activity	Variable transdermal absorption; insufficient for endometrial protection

Evidence for Benefits

Hot Flashes and Vasomotor Symptoms

Soy Isoflavones

Soy isoflavones are the most studied phytoestrogen for hot flash reduction, with dozens of randomized controlled trials published. The evidence is mixed but leans modestly positive for specific formulations and doses.

Meta-analyses and systematic reviews:

A review of clinical studies by Nelson et al. (2006) suggested that a total daily amount of 50-70 mg of soy isoflavones may be effective for reducing hot flashes [20]. A separate analysis by Williamson-Hughes et al. (2006) refined this further, suggesting that at least 15 mg per day specifically of genistein (calculated in aglycone equivalents) is needed, with the total amount of other isoflavones being less important [21]. This finding points to genistein as the critical active component for vasomotor symptom relief.

A 2016 systematic review and meta-analysis published in JAMA by Franco et al. examined plant-based therapies for menopausal symptoms [22]. The review included multiple studies of phytoestrogen supplements and found that phytoestrogens were associated with modest reductions in hot flash frequency compared to placebo, though the magnitude of the effect was clinically questionable in many trials.

Positive trials:

Khaodhiar et al. (2008) found that 28 mg per day of daidzein may be effective for hot flash reduction, suggesting that daidzein alone (not just genistein) may provide benefit at adequate doses [23].

A study using soy germ concentrate (relatively high in daidzein, low in genistein) showed significant hot flash reduction at higher doses, although the daidzein-predominant profile differs substantially from soybean concentrates [10].

Equol production as a modifier:

The inter-individual variation in clinical response to soy isoflavones may be largely explained by equol-producing status. Women who harbor the intestinal bacteria capable of converting daidzein to equol appear to derive greater benefit from soy isoflavone supplementation [11][12]. This has led some researchers to suggest that equol supplements (such as S-equol) may be more consistently effective than standard soy isoflavone preparations, as they bypass the need for metabolic conversion.

Epidemiological context:

Asian women consuming traditional soy-rich diets (approximately 40-80 mg isoflavones daily) consistently report lower rates of menopausal vasomotor symptoms compared to Western women [24][25]. Japanese women report hot flash prevalence as low as 10-20% versus 70-80% in North American cohorts [24]. However, these cross-cultural differences likely reflect multiple factors beyond soy intake, including genetic variation in estrogen metabolism, body composition, and cultural differences in symptom reporting.

Red Clover

The evidence for red clover isoflavones in treating vasomotor symptoms is weaker than for soy isoflavones.

RCT evidence:

Geller et al. (2009) conducted a randomized controlled trial assigning 88 perimenopausal and postmenopausal women (mean age 53 years; 55% from underrepresented minority groups) experiencing at least 35 hot flashes and night sweats per week to one of four groups: 128 mg/day black cohosh extract, 398 mg/day red clover extract (standardized to 120 mg isoflavones), hormone therapy (estrogen and progesterone), or placebo [14]. After 3, 6, 9, and 12 months, vasomotor symptoms declined significantly in all groups, but there were no statistically significant differences between the red clover group and placebo at any time point.

Clinical guideline position:

The generally recommended daily dosage for red clover in treating menopausal symptoms is 40 mg of isoflavones, though the evidence base supporting this dose is thin [10]. Major clinical guidelines do not recommend red clover as an effective treatment for vasomotor symptoms [3][22].

Black Cohosh

Black cohosh has been used for menopausal symptoms since the 1950s, but high-quality evidence of efficacy remains elusive despite numerous studies [15].

High-quality negative trials:

Newton et al. (2006) conducted a rigorous RCT assigning 351 women aged 45-55 years experiencing daytime hot flashes and night sweats to one of five groups [26]:

• 160 mg/day black cohosh (70% ethanolic extract standardized to 2.5% triterpene glycosides)
• A multibotanical preparation containing 200 mg black cohosh plus Siberian ginseng, dong quai, and other ingredients
• The same multibotanical preparation plus two daily servings of soy foods (providing 12-20 g soy protein)
• Hormone therapy (estrogen with or without progesterone)
• Placebo

After 3, 6, and 12 months, the number and intensity of hot flashes and night sweats did not differ between the herbal-intervention groups and placebo, with one exception: at 12 months, participants consuming the multibotanical preparation plus soy foods had significantly worse symptom intensity than those consuming placebo.

Geller et al. (2009) [14], described above, similarly found no statistically significant differences between black cohosh and placebo for vasomotor symptom frequency. The black cohosh group actually showed worse symptom intensity at 6 and 9 months. Secondary endpoints — somatic symptoms (insomnia, fatigue), mood changes (depression, anxiety), and sexual dysfunction (vaginal dryness) — also showed no significant differences between treatment groups at any time point.

Small positive trial:

Mohammad-Alizadeh-Charandabi et al. (2013) reported that a daily dose of just 6.5 mg of a black cohosh extract (standardized to 1.8-2.7% of the triterpene lactone 27-deoxyactein) was effective in an Iranian trial [10]. However, the researchers purchased this product (Cimifugol) from a local pharmacy and did not independently analyze its contents, limiting confidence in the findings. This product does not appear to be available in the United States.

Cochrane Review (2012):

Leach and Moore conducted a Cochrane Review evaluating 16 randomized clinical trials on black cohosh for menopausal symptoms, encompassing a total of 2,027 women (mean age 50.5 to 56.4 years) [3]. Study durations ranged from 8 to 54 weeks (mean 22.8 weeks). Participants received 8 to 160 mg/day of various black cohosh formulations (median dose 40 mg/day). The review concluded that there was "insufficient evidence" from these trials "to either support or oppose the use of black cohosh for menopausal symptoms." The studies were highly heterogeneous with respect to design, duration, type and amount of black cohosh used, and main findings.

Systematic review and meta-analysis (2016):

Franco et al. (2016) examined four black cohosh trials (three from the Cochrane Review above) randomizing a total of 511 women to 6.5-160 mg/day black cohosh extract or placebo [22]. There were no significant associations between black cohosh supplementation and reduction in vasomotor symptom frequency. Furthermore, there were no beneficial associations between black cohosh use and relief of menopausal symptoms using self-reported rating scales.

Clinical guideline positions:

• The American College of Obstetricians and Gynecologists (ACOG), in its 2014 clinical guidelines for managing menopausal symptoms, concluded that "data do not show that" herbal dietary supplements like black cohosh "are efficacious for the treatment of vasomotor symptoms" [27].
• The North American Menopause Society (NAMS) advises clinicians against recommending herbal therapies such as black cohosh because "they are unlikely to be beneficial" (italics in original) in alleviating vasomotor symptoms [18].

Progesterone Cream

The evidence for progesterone cream in treating menopausal hot flashes is limited. The clinical dose shown to have some effect in one trial was 20 mg of progesterone applied daily to the skin [10]. All commercial products provide 20 mg within their suggested dosage ranges. It is not known whether higher doses would be more effective.

Application sites include the upper arms, thighs, or breasts, with daily rotation of the application site recommended. Some protocols suggest discontinuing use for approximately one week each month [10].

Bone Density and Osteoporosis

Soy Isoflavones:

Higher doses of soy isoflavones (above those typically used for hot flashes) have shown some promise for bone density preservation in postmenopausal women.

The OPUS Study: The Osteoporosis Prevention Using Soy (OPUS) study — a large, well-designed trial — found that 120 mg per day of soy isoflavones increased bone density after both one and two years of treatment [28]. However, a lower dose of 80 mg did not show benefit. Critically, bone density improvements were not observed in the most clinically relevant sites — the lumbar spine and hip. The isoflavone product tested was a soy germ concentrate relatively low in genistein (under 10%) and high in daidzein (over 30%).

Bone calcium retention: A study using 105 mg per day of soy isoflavones from Novasoy (taken as 5 tablets with meals) demonstrated a 7.5% improvement in bone calcium retention (Pawlowski et al., Am J Clin Nutr, 2015) [29], a marker of reduced bone turnover.

Genistein-specific evidence: Marini et al. (2007) conducted a small study of genistein alone at 54 mg per day and found increased bone density in both the lumbar spine and hip in postmenopausal women [30] — notably at the clinically important sites where the OPUS study (using a daidzein-predominant product) failed to show benefit. This suggests that genistein may be the more important isoflavone for bone health, consistent with its greater estrogenic potency.

Epidemiological data: Bone density has been shown to be higher among women in Asia who consume roughly 50 mg of isoflavones per day compared to those consuming less [10]. However, lower doses of isoflavones do not appear to be as effective for bone protection in clinical trials.

Black Cohosh: No well-designed clinical trials have demonstrated bone density benefits from black cohosh supplementation. Black cohosh has been found to slightly lower blood pressure and blood sugar in certain animal models, but no bone-specific effects have been reported in human studies [10].

Cholesterol and Cardiovascular Health

For cholesterol reduction, specifically LDL levels, isoflavones alone may not be very helpful [10]. The cardiovascular benefit of soy appears to derive primarily from substituting soy protein for other protein sources rather than from the isoflavone content per se. A diet that replaces animal protein with 25 g/day of soy protein may modestly reduce LDL cholesterol, but this effect is largely independent of isoflavone content.

The broader cardiovascular context is important: menopause is associated with a marked increase in cardiovascular disease risk due to the decline in endogenous estrogen. The Framingham Heart Study reported a 2.6-fold higher incidence of cardiovascular events in postmenopausal versus premenopausal women [5]. Adverse lipid changes — elevated LDL cholesterol and reduced HDL cholesterol — are a direct consequence of estrogen decline [4][5]. In this context, the weak effect of phytoestrogen supplements on lipid profiles is unlikely to meaningfully offset the loss of endogenous estrogen's cardiovascular protection.

Women experiencing premature menopause (before age 40) face a 36% higher total CVD risk, while early menopause (40-44 years) elevates risk by 16%, based on longitudinal cohort data [5]. These elevated risks underscore the importance of evidence-based cardiovascular management (statins, blood pressure control, lifestyle modifications) rather than reliance on phytoestrogen supplements.

Cognitive and Mood Effects

Estrogen decline during menopause is linked to cognitive changes and increased risk of Alzheimer's disease. Systematic reviews have identified earlier age at menopause as a contributing factor to Alzheimer's susceptibility, with women experiencing natural menopause before age 40 facing hazard ratios up to 1.67 for dementia compared to later menopause [31].

However, there is no robust clinical trial evidence demonstrating that phytoestrogen supplements (soy isoflavones, red clover, or black cohosh) meaningfully improve cognitive function or reduce dementia risk in menopausal women. Geller et al. (2009) found no significant differences between black cohosh, red clover, or placebo for mood changes (depression, anxiety) or cognitive symptoms over 12 months [14].

Cognitive behavioral therapy (CBT), delivered in 6-12 sessions, has shown more consistent benefits — decreasing hot flash bother by 40-60% and improving insomnia and mood, independent of age or baseline psychological status [32].

Sleep Disturbances

Sleep disruption is common during menopause, often secondary to night sweats, hormonal changes, and mood disturbances. Up to 70% of menopausal women report sleep problems [2].

Neither soy isoflavones, red clover, nor black cohosh have demonstrated consistent improvements in sleep quality in randomized controlled trials. In the Geller et al. (2009) trial, insomnia was assessed as a secondary endpoint, with no significant differences between any supplement group and placebo [14]. The Newton et al. (2006) trial similarly found no sleep benefits from black cohosh or multibotanical preparations [26].

For sleep disturbances during menopause, interventions with stronger evidence include cognitive behavioral therapy for insomnia (CBT-I), low-dose melatonin, magnesium supplementation, and management of underlying vasomotor symptoms [33][34].

Genitourinary Symptoms

Vaginal dryness and dyspareunia (painful intercourse) affect 50-75% of postmenopausal women as part of genitourinary syndrome of menopause (GSM) [2]. Black cohosh has not shown benefit for vaginal dryness in clinical trials — Geller et al. (2009) found no significant differences for sexual dysfunction endpoints including vaginal dryness [14].

Low-dose topical estrogen remains the gold standard for GSM, with 70-90% of women achieving symptom relief within 12 weeks [6]. Ospemifene (60 mg daily oral SERM) alleviates painful intercourse in 50-60% of women with moderate-to-severe GSM [35]. Over-the-counter vaginal moisturizers and lubricants provide symptomatic relief for milder cases.

Weight and Body Composition

Menopause is associated with increased visceral adiposity and loss of lean muscle mass. A plant-based diet low in refined carbohydrates, supplemented with soy isoflavones, was reported to reduce vasomotor symptom frequency by up to 84% in one intervention trial [36], though this included substantial dietary changes beyond isoflavone supplementation alone.

For menopausal weight management, intentional weight loss of 5-10% body mass through caloric deficit and physical activity eliminates hot flashes in nearly half of cases, as demonstrated in behavioral programs [37]. These effects stem from reduced adipose tissue-derived estrogen and improved thermoregulation.

There are no proven supplements specifically for menopausal weight gain, with limited evidence indicating they are often no better than placebo [38].

Recommended Dosing

Soy Isoflavones

Optimal dosing has not been firmly established, but the following guidelines emerge from clinical evidence:

For hot flash reduction:

• Total isoflavones: 50-70 mg/day of soy isoflavones [20]
• Genistein-specific: At least 15 mg/day of genistein (calculated as aglycone equivalents) may be the critical threshold, with total isoflavone amount being less important [21]
• Daidzein: 28 mg/day may also be effective on its own [23]
• Divide the daily dose into at least two servings to maintain more constant blood levels [10]
• Take with a carbohydrate-rich meal to enhance absorption [10]

For bone density preservation:

• 120 mg/day of soy isoflavones (based on the OPUS study) [28]; lower doses (80 mg) were not effective
• 105 mg/day from Novasoy showed improved bone calcium retention [29]
• 54 mg/day of genistein alone showed benefit at clinically important sites (lumbar spine and hip) [30]
• Higher doses are typically required for bone effects compared to vasomotor symptom relief

For cholesterol: Isoflavones alone are unlikely to provide meaningful LDL reduction [10]. Substituting 25 g/day of soy protein for animal protein may provide modest benefit independent of isoflavone content.

Red Clover

• Standard dose: 40 mg of red clover isoflavones per day [10]
• Higher doses (120 mg isoflavones from 398 mg extract) were tested in the Geller et al. (2009) trial without demonstrating superiority over placebo [14]
• The evidence base for any specific dose is weak

Black Cohosh

• Standard dose: 20 mg of standardized extract once or twice daily (40 mg total), manufactured to contain at least 1 mg of triterpenes per day [10][15]
• The branded product Remifemin provides the equivalent of 40 mg black cohosh root/rhizome per daily dose of two tablets [15][17]
• One study suggested benefit at just 6.5 mg/day, but this has not been independently replicated [10]
• Allow at least 4 weeks of treatment before expecting any symptom improvement [10]
• Most clinical trials have been 6 months or shorter; long-term safety data beyond 6 months are limited [3][15]

Important distinction: Extracts are more concentrated than whole herb or root powder preparations. Less extract is needed to deliver the same amount of triterpenes and other phytochemicals compared to whole-herb products [10].

Progesterone Cream

• Standard dose: 20 mg of progesterone from cream applied daily to the skin [10]
• Application sites: upper arms, thighs, or breasts, rotating location daily
• Consider discontinuing for approximately one week each month [10]
• Must be used under physician supervision as it is a hormone

Dosing Summary Table

Supplement	Indication	Daily Dose	Duration for Effect	Evidence Quality
Soy Isoflavones	Hot flashes	50-70 mg total (≥15 mg genistein)	4-12 weeks	Moderate (mixed results)
Soy Isoflavones	Bone density	120 mg total or 54 mg genistein	12-24 months	Low-Moderate
Red Clover	Hot flashes	40 mg isoflavones	Unknown	Low
Black Cohosh	Hot flashes	20-40 mg extract	4+ weeks	Low (inconsistent)
Progesterone Cream	Hot flashes	20 mg topical	Variable	Low

Safety and Side Effects

Soy Isoflavones

Gastrointestinal effects: GI side effects (bloating, nausea, constipation, diarrhea) may occur in some people taking isoflavone supplements [10].

Breast cancer concerns: There is concern that soy isoflavones may not be safe for women with existing estrogen receptor-positive (ER+) breast cancer or with a family history of breast cancer, due to their estrogenic activity [10]. While epidemiological data from Asian populations suggest that lifelong high soy intake is associated with reduced breast cancer risk, this observation may not apply to concentrated supplement forms initiated later in life, particularly in women with established ER+ tumors.

Uterine stimulation: Most studies have found that isoflavones do not stimulate uterine cells. However, one large study found uterine stimulation in approximately 3% of women, possibly indicating a slightly increased risk of uterine cancer with high-dose isoflavone use (Unfer et al., Fertil Steril, 2004) [39].

Thyroid effects: Soy isoflavone intake may affect thyroid function, potentially increasing the dose of thyroid hormone required in individuals with impaired thyroid function (Messina et al., Thyroid, 2006) [40]. Even in people without thyroid disease, soy isoflavones can cause temporary changes in thyroid markers. A study in adults with normal thyroid function found that consuming approximately 33 mg of aglycone soy isoflavones daily increased levels of rT3 (reverse triiodothyronine) and TSH (thyroid-stimulating hormone), and decreased levels of fT4 (free thyroxine) after 3 months. However, all levels returned to normal after 6 months of continued supplementation (Sathyapalan et al., Front Endocrinol, 2018) [41].

Soy allergy: People with allergies or hypersensitivity to soy products may react to isolated soy isoflavone supplements [10].

Fertility: Although animal data suggested that excessive isoflavone intake may reduce fertility, an observational study of 667 women in the United States (average age 35) seeking infertility care found that even the highest soy intake (0.45 to 7.45+ servings daily) or highest isoflavone intake (approximately 10-166 mg/day — far above the average US daily intake of 2.26 mg) was not associated with a lower ovarian reserve, which is related to pregnancy likelihood and inversely associated with miscarriage risk (Mitsunami et al., Fertil Steril, 2023) [42].

Pregnancy and lactation: Soy isoflavones are not recommended for pregnant or nursing women [10].

Red Clover

Red clover shares the same isoflavone-related safety concerns as soy (breast cancer, thyroid, uterine stimulation) since it contains genistein and daidzein in addition to biochanin A and formononetin. The Geller et al. (2009) trial using 120 mg red clover isoflavones for 12 months did not report serious adverse events, but the sample size (n=22 per group) was too small to detect uncommon adverse effects [14].

Black Cohosh

Common side effects: Gastrointestinal upset is the most frequently reported adverse effect. Other potential side effects include rash, headache, dizziness, weight gain, feeling of heaviness in the legs, and cramping [10][15][43]. Clinical trials have found that the incidence of most adverse effects (breast pain/enlargement, infection, vaginal bleeding/spotting, musculoskeletal complaints) was similar between black cohosh and placebo groups [3].

Hepatotoxicity (liver damage):

This is the most serious safety concern associated with black cohosh. Across the world, at least 83 cases of liver damage — including hepatitis, liver failure, elevated liver enzymes, and other liver injuries — have been associated with black cohosh use [15][43][44]. However, no causal relationship has been established. It is possible that at least some reported cases were due to impurities, adulterants, or incorrect Actaea species in the products used, as no one independently analyzed these products to confirm their identity [3][15][44][45].

Regulatory responses to these reports include:

• New Zealand (2006): Required that black cohosh products carry a warning: "Black cohosh may harm the liver in some individuals. Use under the supervision of a healthcare professional" [10]
• Australia (2007): Required the label statement: "Warning: Black cohosh may harm the liver in some individuals. Use under the supervision of a healthcare professional" [46]
• US Pharmacopeia (2008): Recommended labeling black cohosh products with: "Discontinue use and consult a healthcare practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice" [47]
• The US FDA does not currently require a warning on black cohosh product labels [15]

Cardiac effects:

A case report described a fainting episode due to bradycardia (heart rate below 60 beats per minute) in a 76-year-old woman who had been taking 6.5 to 160 mg of black cohosh twice daily for 10 years for hot flashes [10]. She reported feeling dizzy with increased warmth and palpitations before the fainting episode. Upon discontinuation of black cohosh during hospitalization, her heart rate increased above 60 bpm without requiring a pacemaker, suggesting black cohosh as a potential causal factor. However, the woman also took aspirin, atorvastatin, spironolactone, and amlodipine — both spironolactone and amlodipine have been independently linked to slowing heart rate (Haddad et al., Cureus, 2024; Mc Causland et al., Kidney360, 2023; Tu et al., CRIM, 2020) [48][49][50].

Blood pressure and blood sugar: Animal studies suggest black cohosh may slightly lower blood pressure and blood sugar, raising theoretical concerns about interactions with antihypertensive or antidiabetic medications in humans, though these effects have not been confirmed in clinical studies [10].

Breast cancer: Black cohosh is not recommended for women with existing breast cancer or with a high risk of developing breast cancer, due to potential hormonal interaction [10][15].

Pregnancy and adolescents: Black cohosh is not recommended for pregnant or nursing women, or for adolescents, due to potential hormonal effects [10][15]. The American Herbal Products Association specifically recommends against use during pregnancy unless supervised by a healthcare provider [15].

Confusion with blue cohosh: Black cohosh should not be confused with blue cohosh (Caulophyllum thalictroides), which can cause serious side effects including cardiovascular and neurological toxicity [10].

Long-term safety unknown: Most studies have examined black cohosh use for 6 months or less. No published studies have assessed the long-term safety of black cohosh in humans [15].

Progesterone Cream

• Progesterone cream may cause light spotting but is unlikely to cause other side effects associated with oral progesterone [10]
• Standard doses likely provide too little progesterone to protect the uterus from the stimulating effects of unopposed estrogen — this is a critical safety consideration for women using phytoestrogen supplements alongside progesterone cream [10]
• Extremely small amounts (less than 0.01 mg per gram) of androstenedione may occur as a manufacturing by-product; this is medically insignificant but could trigger positive results in competitive athletes tested for banned substances [10]
• Should only be used under physician supervision as it is a hormone [10]

Safety Summary Table

Supplement	Common Side Effects	Serious Concerns	Contraindications
Soy Isoflavones	GI symptoms	Uterine stimulation (3% of women); thyroid effects	ER+ breast cancer; soy allergy; pregnancy/nursing
Red Clover	GI symptoms	Same concerns as soy isoflavones	ER+ breast cancer; pregnancy/nursing
Black Cohosh	GI upset, headache, rash, dizziness	Hepatotoxicity (83+ case reports); bradycardia	Liver disease; breast cancer; pregnancy; adolescents
Progesterone Cream	Light spotting	Insufficient endometrial protection	Without physician supervision

Drug Interactions

Soy Isoflavones

Simvastatin: Soy isoflavones may reduce the bioavailability of simvastatin (Zocor) in some individuals. A study in 18 healthy young men (average age 27) in China found that taking 80 mg of soy isoflavones daily for 14 days before a single 20 mg dose of simvastatin reduced the active metabolite of simvastatin in the blood by approximately 25% on average (Zeng et al., Front Nutr, 2022) [51]. When analyzed by genotype, this effect was limited to those with the SLCO1B1 521 TT genotype (6 of 18 participants), who showed a 48% reduction on average. Soy isoflavone intake did not reduce simvastatin bioavailability among those with the SLCO1B1 521 CC genotype, which is associated with higher simvastatin exposure and more frequent need for dose adjustment (de Keyser et al., Pharmacogen Genom, 2014) [52].

Other statin interactions: While data are limited to simvastatin, the pharmacokinetic mechanism (likely involving CYP enzyme or transporter modulation) raises theoretical concerns about interactions with other statins, particularly atorvastatin which shares metabolic pathways.

Thyroid medications: Women taking levothyroxine or other thyroid hormone replacement should be aware that soy isoflavones may affect thyroid function and potentially alter thyroid medication requirements [40].

Anticoagulants and antiplatelet agents: No established interactions, but the estrogenic activity of soy isoflavones theoretically could affect coagulation factors.

Black Cohosh

ACE inhibitors and ARBs: Black cohosh may cause significant interactions if taken with ACE inhibitors (e.g., lisinopril, enalapril) or angiotensin receptor blockers (ARBs, e.g., losartan, valsartan) (Page et al., Circulation, 2016) [53].

Amiodarone: Black cohosh may interact with amiodarone, an antiarrhythmic medication [53].

Antihypertensive medications: Based on animal data showing blood pressure-lowering effects, black cohosh could theoretically potentiate the effects of blood pressure medications [10].

Antidiabetic medications: Based on animal data showing blood sugar-lowering effects, black cohosh could theoretically enhance the effects of diabetes medications [10].

Hepatotoxic drugs: Given the reports of liver damage associated with black cohosh, concomitant use with other potentially hepatotoxic medications (acetaminophen at high doses, statins, some antibiotics) warrants caution.

Overall assessment: The NIH Office of Dietary Supplements notes that black cohosh "is not known to have any clinically relevant interactions with medications, although this has not been systematically studied" [15]. The lack of known interactions reflects limited study rather than confirmed safety.

Red Clover

No well-established drug interactions have been identified for red clover specifically, though the same theoretical concerns apply as for soy isoflavones given the shared isoflavone content.

Progesterone Cream

Given that progesterone cream delivers a bioactive hormone, potential interactions exist with:

• Hormonal therapies (estrogen, other progestogens)
• Medications metabolized by CYP3A4 (progesterone is both a substrate and inhibitor)
• Anticoagulants (progesterone may affect clotting factor synthesis)

Drug Interaction Summary

Drug Class	Soy Isoflavones	Red Clover	Black Cohosh	Progesterone Cream
Statins (simvastatin)	May reduce bioavailability by 25-48% (genotype-dependent)	Theoretical (same isoflavones)	No known interaction	No known interaction
Thyroid medications	May alter thyroid function/requirements	Theoretical	No known interaction	No known interaction
ACE inhibitors/ARBs	No known interaction	No known interaction	Potentially significant	No known interaction
Amiodarone	No known interaction	No known interaction	Potentially significant	No known interaction
Antihypertensives	No known interaction	No known interaction	May potentiate (animal data)	No known interaction
Antidiabetic agents	No known interaction	No known interaction	May potentiate (animal data)	No known interaction
Hormonal therapies	Weak additive estrogenic effect	Weak additive estrogenic effect	Unknown mechanism	Additive hormonal effect

Dietary Sources

Soy Isoflavone Content in Foods

For women interested in obtaining isoflavones from dietary sources rather than supplements, soy-based foods and beverages provide naturally occurring isoflavones. The following table lists approximate aglycone isoflavone content per 100 grams of food [10]:

Food	Isoflavones (aglycone) per 100 g
Soy flour (roasted)	199 mg
Soy flour (textured)	148 mg
Soybeans, dry roasted	128 mg
Soy protein concentrate (aqueous washed)	102 mg
Soy protein isolate	97 mg
Soybeans, cooked and boiled	55 mg
Tempeh	44 mg
Miso	43 mg
Tofu	31 mg
Soybean curd cheese	28 mg
Soy protein concentrate (alcohol extracted)	12 mg
Soy milk (3.4 fl oz / 100 mL)	10 mg
Soy noodles	9 mg
Vegetable protein burger	8 mg

Important notes on soy food sources:

• Soy oils and soy lecithin contain no isoflavones [10]
• Soy sauce contains only trace amounts of isoflavones [10]
• The processing method significantly affects isoflavone content: aqueous-washed soy protein concentrate retains 102 mg/100g, while alcohol extraction strips most isoflavones down to 12 mg/100g [10]
• Fermented soy foods (tempeh, miso, natto) may have somewhat higher bioavailability due to partial conversion of glycosides to aglycones during fermentation

Achieving Therapeutic Doses from Diet

To reach the 50-70 mg/day of total isoflavones suggested for vasomotor symptom relief [20], dietary options include:

• Approximately 90-130 g (3-4.5 oz) of cooked soybeans
• 115-160 g (4-5.5 oz) of tempeh
• 160-225 g (5.5-8 oz) of tofu
• 500-700 mL (17-24 oz) of soy milk

Traditional Asian diets typically provide 40-80 mg of isoflavones daily through regular consumption of tofu, miso soup, edamame, and soy milk [24][25]. The average US daily intake of soy isoflavones is approximately 2.26 mg — far below potentially therapeutic levels [42].

Red Clover Dietary Sources

Red clover is not commonly consumed as a food. It is primarily available as standardized extracts in capsule or tablet form, red clover tea (isoflavone content is highly variable and typically much lower than standardized extracts), and dried herb preparations.

Other Phytoestrogen-Rich Foods

Beyond soy and red clover, other foods contain phytoestrogens in varying amounts:

• Flaxseeds — contain lignans, a different class of phytoestrogen; ground flaxseeds provide the highest lignan content. Some intervention trials have shown modest hot flash reduction with flaxseed supplementation [36]
• Legumes (chickpeas, lentils) — contain small amounts of isoflavones
• Whole grains (oats, barley) — contain lignans
• Fruits and vegetables — contain various polyphenols with weak estrogenic activity

Nutritional Strategies for Menopause

A Mediterranean-style or DASH-style diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats provides broader nutritional support during menopause beyond phytoestrogen content [2][36]. Key nutrient targets for menopausal women include:

• Calcium: ≥1,200 mg/day to attenuate bone loss and reduce osteoporosis risk [2]
• Vitamin D: 800-2,000 IU/day to enhance calcium absorption and support bone health [2]
• Protein: 1.1-1.5 g/kg body weight daily to preserve lean muscle mass [2]
• Fiber: 21-30 g/day from whole grains, fruits, vegetables, and legumes [2]
• Omega-3 fatty acids: From fatty fish, flaxseeds, chia seeds, and walnuts for anti-inflammatory benefits [2]

References

1. Freeman EW, Sherif K. "Prevalence of hot flushes and night sweats around the world: a systematic review." Climacteric. 2007;10(3):197-214. https://doi.org/10.1080/13697130601181486

2. Grokipedia. "Menopause." Accessed 2026. https://grokipedia.com/page/Menopause

3. Leach MJ, Moore V. "Black cohosh (Cimicifuga spp.) for menopausal symptoms." Cochrane Database Syst Rev. 2012;(9):CD007244. https://pubmed.ncbi.nlm.nih.gov/22972103/

4. Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. "Symptoms of menopause — global prevalence, physiology and implications." Nat Rev Endocrinol. 2018;14(4):199-215. https://doi.org/10.1038/nrendo.2017.180

5. Kannel WB, Hjortland MC, McNamara PM, Gordon T. "Menopause and risk of cardiovascular disease: the Framingham study." Ann Intern Med. 1976;85(4):447-452. https://doi.org/10.7326/0003-4819-85-4-447

6. The North American Menopause Society. "The 2022 hormone therapy position statement." Menopause. 2022;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028

7. Stuenkel CA, Davis SR, Gompel A, et al. "Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://doi.org/10.1210/jc.2015-2236

8. Patisaul HB, Jefferson W. "The pros and cons of phytoestrogens." Front Neuroendocrinol. 2010;31(4):400-419. https://doi.org/10.1016/j.yfrne.2010.03.003

9. Kuiper GG, Lemmen JG, Carlsson B, et al. "Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta." Endocrinology. 1998;139(10):4252-4263. https://doi.org/10.1210/endo.139.10.6216

10. ConsumerLab. "Menopause Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/soy-isoflavones-red-clover-black-cohosh-supplements/phytoestrogens/

11. Setchell KD, Brown NM, Lydeking-Olsen E. "The clinical importance of the metabolite equol." J Nutr. 2002;132(12):3577-3584. https://doi.org/10.1093/jn/132.12.3577

12. Setchell KD, Clerici C. "Equol: history, chemistry, and formation." J Nutr. 2010;140(7):1355S-1362S. https://doi.org/10.3945/jn.109.119776

13. Booth NL, Piersen CE, Banuvar S, et al. "Clinical studies of red clover dietary supplements in menopause." Menopause. 2006;13(2):251-264. https://doi.org/10.1097/01.gme.0000198297.40269.f7

14. Geller SE, Shulman LP, van Breemen RB, et al. "Safety and efficacy of black cohosh and red clover for vasomotor symptoms." Menopause. 2009;16(6):1156-1166. https://pubmed.ncbi.nlm.nih.gov/19609225/

15. National Institutes of Health, Office of Dietary Supplements. "Black Cohosh — Fact Sheet for Health Professionals." Updated June 3, 2020. https://ods.od.nih.gov/factsheets/BlackCohosh-HealthProfessional/

16. Fabricant DS, Krause EC, Farnsworth NR. "Black cohosh." In: Coates PM, et al., eds. Encyclopedia of Dietary Supplements. 2nd ed. 2010:60-74.

17. Schwabe North America. "Remifemin." Product information.

18. The North American Menopause Society. "Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement." Menopause. 2015;22(11):1155-1172. https://pubmed.ncbi.nlm.nih.gov/26382310/

19. Borrelli F, Izzo AA, Ernst E. "Pharmacological effects of Cimicifuga racemosa." Life Sci. 2003;73(10):1215-1229. https://pubmed.ncbi.nlm.nih.gov/12850238/

20. Nelson HD, Vesco KK, Haney E, et al. "Nonhormonal therapies for menopausal hot flashes." JAMA. 2006;295(17):2057-2071. https://doi.org/10.1001/jama.295.17.2057

21. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. "Isoflavone supplements containing predominantly genistein reduce hot flash symptoms." Menopause. 2006;13(5):831-839. https://doi.org/10.1097/01.gme.0000227330.49081.9e

22. Franco OH, Chowdhury R, Troup J, et al. "Use of Plant-Based Therapies and Menopausal Symptoms." JAMA. 2016;315(23):2554-2563. https://pubmed.ncbi.nlm.nih.gov/27327802/

23. Khaodhiar L, Ricciotti HA, Li L, et al. "Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes." Menopause. 2008;15(1):125-132. https://doi.org/10.1097/gme.0b013e31805c035b

24. Lock M. Encounters with aging: mythologies of menopause in Japan and North America. University of California Press; 1993.

25. Adlercreutz H, Mazur W. "Phyto-oestrogens and Western diseases." Ann Med. 1997;29(2):95-120. https://doi.org/10.3109/07853899709113696

26. Newton KM, Reed SD, LaCroix AZ, et al. "Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo." Ann Intern Med. 2006;145(12):869-879. https://pubmed.ncbi.nlm.nih.gov/17179056/

27. ACOG Practice Bulletin No. 141. "Management of menopausal symptoms." Obstet Gynecol. 2014;123(1):202-216. https://pubmed.ncbi.nlm.nih.gov/24463691/

28. Wong WW, Lewis RD, Steinberg FM, et al. "Soy isoflavone supplementation and bone mineral density (OPUS study)." Am J Clin Nutr. 2009;90(5):1433-1439. https://doi.org/10.3945/ajcn.2009.28001

29. Pawlowski JW, Martin BR, McCabe GP, et al. "Impact of equol-producing capacity and soy-isoflavone profiles on bone calcium retention." Am J Clin Nutr. 2015;102(3):695-703. https://doi.org/10.3945/ajcn.114.093906

30. Marini H, Minutoli L, Polito F, et al. "Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women." Ann Intern Med. 2007;146(12):839-847. https://doi.org/10.7326/0003-4819-146-12-200706190-00005

31. Gilsanz P, Lee C, Corrada MM, et al. "Reproductive period and risk of dementia." Neurology. 2019;92(17):e2038-e2046. https://doi.org/10.1212/WNL.0000000000007326

32. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. "Effectiveness of group and self-help CBT in reducing menopausal hot flushes (MENOS 2)." Menopause. 2012;19(7):749-759. https://doi.org/10.1097/gme.0b013e31823cc5f4

33. Low TL, Choo FN, Tan SM. "The efficacy of melatonin and melatonin agonists in insomnia." J Psychiatr Res. 2020;121:10-23. https://doi.org/10.1016/j.jpsychires.2019.11.001

34. Arab A, Rafie N, Amani R, Shirani F. "The Role of Magnesium in Sleep Health." Biol Trace Elem Res. 2023;201(7):3171-3179. https://doi.org/10.1007/s12011-022-03232-w

35. Portman DJ, Bachmann GA, Simon JA. "Ospemifene for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy." Menopause. 2013;20(6):623-630. https://doi.org/10.1097/gme.0b013e318279ba64

36. Barnard ND, Kahleova H, Holtz DN, et al. "The WAVS trial: a plant-based diet and whole soybeans for postmenopausal women." Menopause. 2021;28(10):1150-1156. https://doi.org/10.1097/GME.0000000000001812

37. Huang AJ, Subak LL, Wing R, et al. "An intensive behavioral weight loss intervention and hot flushes in women." Arch Intern Med. 2010;170(13):1161-1167. https://doi.org/10.1001/archinternmed.2010.162

38. Harvard Health Publishing. "Supplements for menopause symptoms." Harvard Medical School. https://www.health.harvard.edu/womens-health/menopause-and-supplements

39. Unfer V, Casini ML, Costabile L, et al. "Endometrial effects of long-term treatment with phytoestrogens." Fertil Steril. 2004;82(1):145-148. https://doi.org/10.1016/j.fertnstert.2003.11.041

40. Messina M, Redmond G. "Effects of soy protein and soybean isoflavones on thyroid function." Thyroid. 2006;16(3):249-258. https://doi.org/10.1089/thy.2006.16.249

41. Sathyapalan T, Dawson AJ, Sherif M, et al. "Effect of Soy Phytoestrogen Supplementation on Thyroid Status." Front Endocrinol. 2018;9:531. https://doi.org/10.3389/fendo.2018.00531

42. Mitsunami M, Gaskins AJ, Rich-Edwards JW, et al. "Soy food and isoflavone intake and ovarian reserve." Fertil Steril. 2023;120(2):413-421. https://doi.org/10.1016/j.fertnstert.2023.03.024

43. Borrelli F, Ernst E. "Black cohosh: a systematic review of adverse events." Am J Obstet Gynecol. 2008;199(5):455-466. https://pubmed.ncbi.nlm.nih.gov/18722570/

44. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, et al. "Herb induced liver injury presumably caused by black cohosh." Ann Hepatol. 2011;10(3):249-259. https://pubmed.ncbi.nlm.nih.gov/21677327/

45. Betz JM, Anderson L, Avigan MI, et al. "Black cohosh: considerations of safety and benefit." Nutr Today. 2009;44(4):155-162.

46. Australian Government Department of Health, Therapeutic Goods Administration. "New labelling requirements for medicines containing black cohosh." 2007.

47. Mahady GB, Low Dog T, Barrett ML, et al. "USP review of black cohosh case reports of hepatotoxicity." Menopause. 2008;15(4):628-638. https://pubmed.ncbi.nlm.nih.gov/18340277/

48. Haddad A, et al. "Black Cohosh-Associated Bradycardia." Cureus. 2024.

49. Mc Causland FR, et al. "Spironolactone and heart rate." Kidney360. 2023.

50. Tu G, et al. "Amlodipine-associated bradycardia." CRIM. 2020.

51. Zeng Y, Fang Q, Chen M, et al. "Soy isoflavones affect the pharmacokinetics of simvastatin." Front Nutr. 2022;9:983686. https://doi.org/10.3389/fnut.2022.983686

52. de Keyser CE, Peters BJ, Becker ML, et al. "The SLCO1B1 c.521T>C polymorphism and statin therapy." Pharmacogenet Genomics. 2014;24(1):43-51. https://doi.org/10.1097/FPC.0000000000000018

53. Page RL 2nd, O'Bryant CL, Cheng D, et al. "Drugs That May Cause or Exacerbate Heart Failure." Circulation. 2016;134(6):e32-e69. https://pubmed.ncbi.nlm.nih.gov/27400984/